Research recommendation(s) from an individual piece of guidance
|Guidance:||Renal cell carcinoma - sunitinib|
|Date issued:||March 2009|
Research recommendations coming out of this guidance
- [NICE] considered that the following well conducted [randomised controlled trials] RCTs reporting health-related utility values in accordance with the NICE...
- [NICE] considered that rigorous data collection is needed on the life-extending benefits of sunitinib when no second-line treatments are given.
This page was last updated: 14 November 2013